Pyrazine derivatives

Abstract

The invention concerns pyrazine derivatives of the Formula I or pharmaceutically-acceptable salts thereof; wherein each of n, m and R has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of bone-related disorders or conditions.

1 - 9 . (canceled) 
     
     
         10 . A method for the treatment of a warm-blooded animal having a bone-related disorder or condition, which is sensitive to inhibition of GSK-3 enzymes, which comprises administering to said animal an effective amount of a compound of the Formula I: 
       
         
           
           
               
               
           
         
         in which: 
         n is 2 or 3; 
         m is 2 or 3; 
         R is methyl or ethyl; 
         or a pharmaceutically-acceptable salt thereof. 
       
     
     
         11 - 12 . (canceled) 
     
     
         13 . A method for promoting bone formation in a warm-blooded animal, which comprises administering to said animal an effective amount of a compound of the Formula I 
       
         
           
           
               
               
           
         
         in which: 
         n is 2 or 3; 
         m is 2 or 3; 
         R is methyl or ethyl; 
         or a pharmaceutically-acceptable salt thereof. 
       
     
     
         14 - 15 . (canceled) 
     
     
         16 . A method for treating bone lesions in cancers such as for example cancers of the breast, prostate and lung, multiple myeloma, osteosarcoma, Ewing's sarcoma, chondrosarcoma, chordoma, malignant fibrous histiocytoma of the bone, fibrosarcoma of the bone, cancer induced bone disease, iatrogenic bone disease, benign bone disease and Paget's disease in a warm-blooded animal, which comprises administering to said animal an effective amount of a compound of the Formula I: 
       
         
           
           
               
               
           
         
         in which: 
         n is 2 or 3; 
         m is 2 or 3; 
         R is methyl or ethyl; 
         or a pharmaceutically-acceptable salt thereof. 
       
     
     
         17 . (canceled) 
     
     
         18 . A method according to  claim 16 , wherein the cancer is multiple myeloma. 
     
     
         19 . A method according to  claim 10 ,  13  or  16 , wherein the compound of formula I is 3-amino-6-(4-{3-[(3-methoxypropyl)amino]propyl}phenyl)-N-pyridin-3-ylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt thereof. 
     
     
         20 . A method of  claim 19 , wherein the compound of formula I is a pharmaceutically acceptable salt of 3-amino-6-(4-{3-[(3-methoxypropyl)amino]propyl}phenyl)-N-pyridin-3-ylpyrazine-2-carboxamide. 
     
     
         21 . A method of  claim 20 , wherein the pharmaceutically acceptable salt is a tri-hydrochloride, a mono-besylate or a mono-tosylate salt.